PAR. SP, page-809

If you circle back to the 008 study and look at the p values…. there is your look through.

if you dig up the old 005 study and look at the p values, there is your look through.

If you look at the MRI outcomes, Biomarker data, there is your look through.

The dosing stage 1 arm, doesn’t have the 2mg/kg twice weekly dose in it, hence the importance of the protocol review with the FDA coming up this quarter.

Paul said on the recent unicorn podcast that the dosing arm of phase 3 (stage 1) proved “beyond doubt” there is one dose performing better than any other…. And it’s the 2mg/kg twice weekly…. The one we have the most data on and have used basically exclusively for years.